Transient receptor potential vanilloid 1 (TRPV1) is a nonselective cation channel with high permeability for Ca 2ϩ , primarily expressed in central and peripheral terminals of non-myelinated primary afferent neurons. 1,2) In addition to chemical ligands such as capsaicin, TRPV1 receptors are also activated by other stimuli such as protons, heat, and some endogenous vanilloids. 3,4) Desensitization of TRPV1 by capsaicin is clinically effective in treating a variety of neuropathic pain conditions. Further, a considerable number of TRPV1 antagonists have shown efficacy in several pain models. 5) Therefore, inhibition of TRPV1 function is an attractive target for treating chronic intractable pain. In contrast, TRPV1 is known to be involved in thermoregulation and antagonism can cause hyperthermia as a side effect. However, recent reports showed that TRPV1 antagonists that can prevent ligand-induced activation without affecting receptor activation by protons have minimal effects on body temperature. 6) We have shown previously that (R)-N-(1-methyl-2-oxo-1,2,3,4-tetrahydro-7-quinolyl)-2-[(2-methylpyrrolidin-1-yl)methyl]biphenyl-4-carboxamide (AS1928370) belongs to this group of TRPV1 antagonists, and that it ameliorates neuropathic pain in rats without inducing hyperthermic effects. 7) However, there are few reports regarding the site of action of this type of TRPV1 antagonist in neuropathic pain models, and thus further study is needed.One of the most commonly used model of neuropathic pain is a L5/L6 spinal nerve ligation (SNL) model in rats. Although there have been some investigations of partial sciatic nerve ligation and L5 SNL model using mice, however there have been few studies using L5/L6 SNL model in mice. We previously established the L5/L6 SNL model in mice, which represented a more robust mechanical allodynia and a superior predictive validity than L5 SNL. 8) We also showed that a direct intrathecal (i.t.) injection technique could be applied in this model. This method in unanesthetized mice allows reliable, rapid, and easy evaluation of drug effects without complicated surgery. Here, we assess the pharmacokinetics and in vivo TRPV1 antagonist activity of AS1928370 in mice, and evaluate the analgesic effects of orally and intrathecally administered AS1928370 to investigate the action site of TRPV1 antagonists in an SNL model. In addition, we examined the effects of AS1928370 on locomotion to characterize the side effect profile of this drug in mice.
MATERIALS AND METHODSMaterials (R)-N-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-7-quinolyl)-2-[(2-methylpyrrolidin-1-yl)methyl]biphenyl-4-carboxamide (AS1928370) was synthesized at Astellas Pharma Inc. (Tsukuba, Japan). A monohydrochloride salt of AS1928370 was used as AS1928370. AS1928370 was suspended in 0.5% methylcellulose aqueous solution and administered orally in a volume of 10 ml/kg, or dissolved in 20% 2-hydroxypropyl-b-cyclodextrin and administered intrathecally (i.t.) in a volume of 5 ml in unanesthetized mice according to the method established by Hylden a...